- $166.46m
- $85.46m
- $79.87m
- 50
- 33
- 11
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.9 | ||
| Price to Tang. Book | 1.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.08 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.21% | ||
| Return on Equity | -49.59% | ||
| Operating Margin | -65.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 27.64 | 48.96 | 71.33 | 81.06 | 79.87 | 72.13 | 80.19 | 27.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Directors
- Staffan Encrantz CHM (69)
- Paul Badawi PRE (46)
- David Badawi CFD (51)
- Jesse Selnick CFO (46)
- Sam Park COO (60)
- Ingrid Kane VPR
- John Ordway VPR
- Jeremy Hayden OTH (51)
- Shawn O'Neil OTH (48)
- Mack Hicks DRC (40)
- Andrew Offer DRC (38)
- Erica Rogers DRC (58)
- Valeska Schroeder DRC (48)
- Donald Zurbay DRC (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 10th, 2010
- Public Since
- July 15th, 2021
- No. of Shareholders
- 9
- No. of Employees
- 216
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 51,695,688
- Address
- 4040 Campbell Ave,, Suite 100, MENLO PARK, 94025
- Web
- https://www.sightsciences.com/
- Phone
- +1 4158890550
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SGHT
Q1 2025 Sight Sciences Inc Earnings Release
Sight Sciences Inc Annual Shareholders Meeting
Sight Sciences Inc Annual Shareholders Meeting
Q2 2025 Sight Sciences Inc Earnings Release
Similar to SGHT
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Sight Sciences share price?
As of Today at 23:14 UTC, shares in Sight Sciences are trading at $3.22. This share price information is delayed by 15 minutes.
How has the Sight Sciences share price performed this year?
Shares in Sight Sciences last closed at $3.22 and the price had moved by -37.35% over the past 365 days. In terms of relative price strength the Sight Sciences share price has underperformed the S&P500 Index by -42.18% over the past year.
What are the analyst and broker recommendations for Sight Sciences?
The overall consensus recommendation for Sight Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sight Sciences dividend yield?
Sight Sciences does not currently pay a dividend.
Does Sight Sciences pay a dividend?
Sight Sciences does not currently pay a dividend.
When does Sight Sciences next pay dividends?
Sight Sciences does not currently pay a dividend.
How do I buy Sight Sciences shares?
To buy shares in Sight Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sight Sciences?
As of the previous close price of $3.22, shares in Sight Sciences had a market capitalisation of $166.46m.
Where are Sight Sciences shares listed?
Here are the trading details for Sight Sciences:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SGHT
What kind of share is Sight Sciences?
Based on an overall assessment of its quality, value and momentum Sight Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sight Sciences share price forecast for 2025?
The analyst consensus target price for shares in Sight Sciences is $3.42. That is 6.21% above the last closing price of $3.22.
Analysts covering Sight Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.10 for the next financial year.
Find out moreWhat is the trend in the Sight Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sight Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -34.73%.
As of the last closing price of $3.22, shares in Sight Sciences were trading -28.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sight Sciences PE Ratio?
The Sight Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sight Sciences?
Sight Sciences' management team is headed by:
- Staffan Encrantz - CHM
- Paul Badawi - PRE
- David Badawi - CFD
- Jesse Selnick - CFO
- Sam Park - COO
- Ingrid Kane - VPR
- John Ordway - VPR
- Jeremy Hayden - OTH
- Shawn O'Neil - OTH
- Mack Hicks - DRC
- Andrew Offer - DRC
- Erica Rogers - DRC
- Valeska Schroeder - DRC
- Donald Zurbay - DRC